Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis

被引:9
|
作者
Kelly, Bridget N. [1 ]
Webster, Alexandra J. [1 ]
Lamb, Leslie [2 ]
Spivey, Tara [1 ]
Korotkin, Jenna E. [1 ]
Henriquez, Anthony [1 ]
Gadd, Michele A. [1 ]
Hughes, Kevin S. [1 ]
Lehman, Constance R. [2 ]
Smith, Barbara L. [1 ]
Specht, Michelle C. [1 ]
机构
[1] Massachusetts Gen Hosp, Div Surg Oncol, Yawkey 7,55 Fruit St, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Radiol, Boston, MA 02114 USA
关键词
Breast conserving surgery; Magnetic seed localization; Wireless localization; Lumpectomy; Preoperative; identification (RFID) seeds; nonradioactive radar localization (SAVI; ONCOLOGY CONSENSUS GUIDELINE; CONSERVING SURGERY; AMERICAN SOCIETY; LOCALIZATION; IRRADIATION; MARGINS; LESIONS; SYSTEM;
D O I
10.1016/j.clbc.2022.01.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Magnetic seed is an alternative to wires for localization of nonpalpable breast lesions that uses a wireless detector probe to guide the surgeon to an implanted magnetic seed. Operative time, specimen volume, postoperative opioid administration, and re-excision rate were compared between the 2 cohorts. We found magnetic seeds to be a feasible alternative to wires with regard to surgical outcomes. Introduction: Magnetic seeds have emerged as an alternative to wires for localization of nonpalpable breast lesions. The purpose of this study was to evaluate the utility of magnetic seeds compared to wires for preoperative localization. Materials and Methods: A retrospective cohort analysis of magnetic seed localization (MSL) and wire localization (WL) excisional biopsies and lumpectomies performed at a single institution was conducted. Indication, age, BMI, number of markers, procedure type, operative time, and postoperative opioid administration were reviewed. Impact of localization method on operative time, specimen volume, postoperative opioid administration, and re-excision rate were assessed. Results: A total of 608 MSL procedures in 601 patients were compared to 628 WL procedures in 620 patients. MSL excisional biopsies were significantly longer (37.0 minutes) than WL excisional biopsies (31.9 minutes, P < .001), but in lumpectomies without axillar y surger y, MSL procedures (42.3 minutes) were significantly shorter than WL procedures (46.9 minutes, P = .017). Significantly less tissue was excised during MSL lumpectomies (68.5 cm 3 ) and excisional biopsies (32.3 cm 3 ) than WL lumpectomies (78.1 cm 3 , P = .039) and excisional biopsies (38.7 cm 3 , P = .018). Postoperative opioid administration was similar for MSL and WL procedures ( P = .076). Re-excision rates for MSL lumpectomies were significantly higher for ductal carcinoma in situ (35.3% MSL vs. 18.5% WL, P = .013), but were similar for invasive carcinoma (14.4% MSL vs. 17.7% WL, P = .290). Logistic regression analysis showed no association between localization method and re-excision (OR 1.007, 95% CI 0.681-1.488; P = .973). Conclusion: MSL is a feasible alternative to WL for excision of nonpalpable breast lesions with regard to surgical outcomes.
引用
收藏
页码:E700 / E707
页数:8
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
    Zhang, Miaomiao
    Huang, Jinlong
    Zheng, Xiaochun
    Huang, Ping
    Yang, Xiuli
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [22] COST-EFFECTIVENESS ANALYSIS OF TRASUTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR WOMEN WITH HER2+ADJUVANT BREAST CANCER IN FRANCE
    Gherardi, A.
    Sellami, R.
    Tehard, B.
    Roze, S.
    VALUE IN HEALTH, 2019, 22 : S459 - S459
  • [23] TRASTUZUMAB IN METASTATIC BREAST CANCER: A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES
    Andrade, T. S. D.
    Mosegui, G. B. G.
    Miranda, E. S.
    Souza, T. F. G. D.
    Vianna, C. M. D. M.
    Silva, F. V. C.
    VALUE IN HEALTH, 2013, 16 (07) : A687 - A687
  • [24] Cost-effectiveness analysis of trastuzumab therapy in patients with early HER-2 positive breast cancer in Brazil
    Vernaglia, P. R.
    Cunha, F. M.
    Correa, M.
    Perdicaris, M. R.
    Saggia, M. G.
    Santos, E. A., V
    Nasciben, V. D.
    Pelizon, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S106 - S106
  • [25] Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States
    Bs, Ye Peng
    Wang, Liting
    Peng, Liubao
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    Chen, Guochun
    CLINICAL THERAPEUTICS, 2023, 45 (10) : 965 - 972
  • [26] Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
    Shi, Demin
    Liang, Xueyan
    Li, Yan
    Chen, Lingyuan
    PLOS ONE, 2023, 18 (08):
  • [27] Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States
    Mudumba, Rahul
    Chan, Hui-Hsuan
    Cheng, Yuan-Yuan
    Wang, Chien-Chen
    Correia, Luis
    Ballreich, Jeromie
    Levy, Joseph
    VALUE IN HEALTH, 2024, 27 (02) : 153 - 163
  • [28] Cost-effectiveness analysis of advanced radiotherapy techniques for post-mastectomy breast cancer patients
    Xie, Yibo
    Guo, Beibei
    Zhang, Rui
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2020, 18 (01)
  • [29] Cost-effectiveness analysis of advanced radiotherapy techniques for post-mastectomy breast cancer patients
    Yibo Xie
    Beibei Guo
    Rui Zhang
    Cost Effectiveness and Resource Allocation, 18
  • [30] Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
    Xu, Qiaoping
    Li Yuanyuan
    Zhu Jiejing
    Liu Jian
    Li Qingyu
    Chen Lingya
    Luo Ying
    Shi Changchen
    Li Yangling
    Yan Wei
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)